ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Iowa's MULTIDISCIPLINARY CANCER CARE TEAM and the PATIENTS THEY SERVE since 1992
Meetings & Education
State Society Education Series
Allied Health Professionals Award
Financial Advocacy & Patient Assistance
IOS Advocacy Support
Patient Advocacy Organizations
IOS Quality Award Program
State & Federal Resources
Find A Clinical Trial
Off-Label Use Literature
National Professional Organizations
IOS Corporate Members
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Approves Niraparib for HRD-positive Advanced Ovarian Cancer
On October 23, 2019, the U.S. Food and Drug Administration (FDA) approved niraparib (Zejula, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious
mutation, or genomic instability in patients with disease progression greater than six months after response to the last platinum-based chemotherapy.
The FDA also approved the
Myriad myChoice CDx test
for determination of tumor HRD status to select patients for niraparib.
Read the FDA announcement
on FDA-approved test for detection of deleterious or suspected deleterious BRCA mutation and/or genomic instability for this indication.